To include your compound in the COVID-19 Resource Center, submit it here.

APF 112: Phase I complete

APPA withdrew the proposed protocol for a Phase II study of its APF 112 treat short-term

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE